APA (7th ed.) Citation

Wilbraham, D., Biglan, K. M., Svensson, K. A., Tsai, M., & Kielbasa, W. (2021). Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects. Clinical pharmacology in drug development, 10(4), 393-403. https://doi.org/10.1002/cpdd.874

Chicago Style (17th ed.) Citation

Wilbraham, Darren, Kevin M. Biglan, Kjell A. Svensson, Max Tsai, and William Kielbasa. "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects." Clinical Pharmacology in Drug Development 10, no. 4 (2021): 393-403. https://doi.org/10.1002/cpdd.874.

MLA (9th ed.) Citation

Wilbraham, Darren, et al. "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects." Clinical Pharmacology in Drug Development, vol. 10, no. 4, 2021, pp. 393-403, https://doi.org/10.1002/cpdd.874.